Literature DB >> 1729362

Induction of IFN-alpha in peripheral blood mononuclear cells by HIV-infected monocytes. Restricted antiviral activity of the HIV-induced IFN.

H E Gendelman1, L M Baca, C A Kubrak, P Genis, S Burrous, R M Friedman, D Jacobs, M S Meltzer.   

Abstract

PBMC cocultured with HIV-infected monocytes for 12 to 48 h released high levels of IFN activity. IFN titers were directly dependent upon time after virus infection and level of HIV replication in infected cells. IFN induction in PBMC was evident with HIV-infected monocytes and PBMC and with myeloid and lymphoblastoid cell lines with at least three different HIV strains. In HIV-infected cell line pairs in which virus infection occurs in both productive and restricted forms, IFN induction in PBMC occurred only with productive infection. IFN activity was acid stable and completely neutralized by antibodies against IFN-alpha. Induction of IFN required cell-cell contact between HIV-infected cells and PBMC, but was independent of MHC compatibility. With PBMC co-cultured with autologous HIV-infected monocytes, IFN induction was highly selective: IL-1 beta, IL-6, or TNF-alpha activity and mRNA were not detected. Cell surface determinants on HIV-infected monocytes that induced IFN in PBMC remained active after fixation in 4% paraformaldehyde. Both adherent and nonadherent PBMC produced IFN after coculture with HIV-infected monocytes. Ability to produce IFN by PBMC was not affected by depletion of T cell, NK cell, B cell, or monocyte subpopulations. The IFN activity produced by PBMC cocultured with HIV-infected cells was about 20-fold less active than equal quantities of rIFN-alpha 2b for inhibition of HIV replication in monocytes and at low concentrations enhanced virus growth. Clinical studies with HIV-infected patients and parallel findings in animal lentivirus disease suggest an adverse role for IFN in disease progression. Conditions for induction of IFN in the culture system described in this report may mimic those in the HIV-infected patient. Defining the molecular basis for IFN induction, the cells that produce IFN, and the altered biologic activity of this important cytokine may provide insight into the pathogenesis of HIV disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1729362

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway.

Authors:  Nancy Q Liu; Albert S Lossinsky; Waldemar Popik; Xia Li; Chandrasekhar Gujuluva; Benjamin Kriederman; Jaclyn Roberts; Tatania Pushkarsky; Michael Bukrinsky; Marlys Witte; Martin Weinand; Milan Fiala
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

2.  Potent strategy to inhibit HIV-1 by binding both gp120 and gp41.

Authors:  Ioannis Kagiampakis; Arbi Gharibi; Marie K Mankowski; Beth A Snyder; Roger G Ptak; Kristabelle Alatas; Patricia J LiWang
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

3.  Highly potent chimeric inhibitors targeting two steps of HIV cell entry.

Authors:  Bo Zhao; Marie K Mankowski; Beth A Snyder; Roger G Ptak; Patricia J Liwang
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

4.  The role of individual carbohydrate-binding sites in the function of the potent anti-HIV lectin griffithsin.

Authors:  Jie Xue; Yongguang Gao; Bart Hoorelbeke; Ioannis Kagiampakis; Bo Zhao; Borries Demeler; Jan Balzarini; Patricia J Liwang
Journal:  Mol Pharm       Date:  2012-08-21       Impact factor: 4.939

5.  Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.

Authors:  E Randall Lanier; Roger G Ptak; Bernhard M Lampert; Laurie Keilholz; Tracy Hartman; Robert W Buckheit; Marie K Mankowski; Mark C Osterling; Merrick R Almond; George R Painter
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

6.  Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

Authors:  Joseph F Bower; Xinzhen Yang; Joseph Sodroski; Ted M Ross
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

7.  Induction of beta interferon by human immunodeficiency virus type 1 and its gp120 protein in human monocytes-macrophages: role of beta interferon in restriction of virus replication.

Authors:  S Gessani; P Puddu; B Varano; P Borghi; L Conti; L Fantuzzi; F Belardelli
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  Cytokine-mediated regulation of monocyte/macrophage cytotoxicity in human immunodeficiency virus-1 infection.

Authors:  S Rossol; G Gianni; R Rossol-Voth; H Gallati; W E Müller; K H Meyer zum Büschenfelde
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

9.  Alpha interferon-induced antiretroviral activities: restriction of viral nucleic acid synthesis and progeny virion production in human immunodeficiency virus type 1-infected monocytes.

Authors:  L Baca-Regen; N Heinzinger; M Stevenson; H E Gendelman
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

10.  Induction of interleukin-10 by human immunodeficiency virus type 1 and its gp120 protein in human monocytes/macrophages.

Authors:  P Borghi; L Fantuzzi; B Varano; S Gessani; P Puddu; L Conti; M R Capobianchi; F Ameglio; F Belardelli
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.